{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:54:36Z","timestamp":1767707676137,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007950","name":"Tanta University","doi-asserted-by":"publisher","award":["36264PR880\/9\/24"],"award-info":[{"award-number":["36264PR880\/9\/24"]}],"id":[{"id":"10.13039\/501100007950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clinthera.2025.04.019","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T23:32:13Z","timestamp":1748043133000},"page":"e1-e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Diagnostic and Prognostic Roles of Inflammatory Biomarkers in Patients With Coronary Heart Disease and Heart Failure Treated With Empagliflozin"],"prefix":"10.1016","volume":"47","author":[{"given":"Ahmed A.","family":"El-Sherbeni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naglaa F.","family":"Khedr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibtsam","family":"Khairat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5983-3993","authenticated-orcid":false,"given":"Rehab H.","family":"Werida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.04.019_bib0001","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0002","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics\u20142020 update: a report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2025.04.019_bib0003","first-page":"S36","article-title":"Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden","volume":"15","author":"Kolansky","year":"2009","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0004","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1161\/CIRCULATIONAHA.112.125435","article-title":"Rehospitalization for heart failure: predict or prevent?","volume":"126","author":"Desai","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","article-title":"Epidemiology of heart failure","volume":"113","author":"Roger","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0006","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics\u20142017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0007","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1161\/CIR.0b013e31820a55f5","article-title":"Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association","volume":"123","author":"Heidenreich","year":"2011","journal-title":"Circulation"},{"year":"2018","series-title":"What\u2019s New in the Fourth Universal Definition of Myocardial Infarction?","author":"Thygesen","key":"10.1016\/j.clinthera.2025.04.019_bib0008"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0009","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.CIR.0000053730.47739.3C","article-title":"Clinical application of C-reactive protein for cardiovascular disease detection and prevention","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0010","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrendo.2012.258","article-title":"The role of hepatokines in metabolism","volume":"9","author":"Stefan","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0011","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1373\/clinchem.2003.021634","article-title":"Facts and recommendations about total homocysteine determinations: an expert opinion","volume":"50","author":"Refsum","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0012","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cmet.2010.08.006","article-title":"Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export","volume":"12","author":"Kjolby","year":"2010","journal-title":"Cell Metab"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0013","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1126\/science.1097243","article-title":"Visfatin: a protein secreted by visceral fat that mimics the effects of insulin","volume":"307","author":"Fukuhara","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0014","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.bbrc.2005.11.039","article-title":"Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes","volume":"339","author":"Kl\u00f6ting","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0015","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0016","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/clinchem\/20.4.470","article-title":"Enzymatic determination of total serum cholesterol","volume":"20","author":"Allain","year":"1974","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0017","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0018","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0019","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/CIRCULATIONAHA.105.588723","article-title":"Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study","volume":"113","author":"Ix","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0020","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0735-1097(02)02824-3","article-title":"Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients","volume":"41","author":"Kaul","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0021","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1159\/000533266","article-title":"Cardiac troponin T and NT-proBNP for prediction of 30-day readmission or death in patients with acute dyspnea: data from the Akershus Cardiac Examination 2 Study","volume":"148","author":"Bhatnagar","year":"2023","journal-title":"Cardiology"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0022","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3121\/cmr.2020.1513","article-title":"Inpatient mortality and 30-day readmission rates associated with troponin testing in patients without acute myocardial infarction","volume":"18","author":"Widmer","year":"2020","journal-title":"Clin Med Res"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0023","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jchf.2017.11.003","article-title":"High-sensitivity cardiac troponin and new-onset heart failure: a systematic review and meta-analysis of 67,063 patients with 4,165 incident heart failure events","volume":"6","author":"Evans","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0024","doi-asserted-by":"crossref","first-page":"R636","DOI":"10.1186\/cc3816","article-title":"Elevated troponin and myocardial infarction in the intensive care unit: a prospective study","volume":"9","author":"Lim","year":"2005","journal-title":"Crit Care"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0025","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0026","doi-asserted-by":"crossref","first-page":"483","DOI":"10.7326\/0003-4819-151-7-200910060-00009","article-title":"C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force","volume":"151","author":"Buckley","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0027","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-39051-3","article-title":"Association between high-sensitivity C-reactive protein and coronary atherosclerosis in a general middle-aged population","volume":"13","author":"Cederstr\u00f6m","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0028","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"S","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0029","first-page":"211","article-title":"Associations between vaspin levels and coronary artery disease","volume":"4","author":"Askin","year":"2020","journal-title":"Cardiovasc Innov Appl"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0030","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.hlc.2015.07.001","article-title":"Vaspin as a prognostic marker in patients with acute myocardial infarction","volume":"25","author":"Zhang","year":"2016","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0031","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010934","article-title":"Serum vaspin as a predictor of adverse cardiac events in acute myocardial infarction","volume":"8","author":"Zhou","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0032","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1161\/ATVBAHA.117.309700","article-title":"Lower plasma fetuin-A levels are associated with a higher mortality risk in patients with coronary artery disease","volume":"37","author":"Chen","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0033","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jacc.2012.01.038","article-title":"The association of fetuin-A with cardiovascular disease mortality in older community-dwelling adults: the Rancho Bernardo study","volume":"59","author":"Laughlin","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0034","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/bmj.325.7374.1202","article-title":"Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis","volume":"325","author":"Wald","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0035","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2147\/TCRM.S239496","article-title":"Homocysteine and the risk of cardiovascular events and all-cause death in elderly population: a community-based prospective cohort study","volume":"16","author":"Zhang","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0036","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026875","article-title":"Elevated homocysteine levels in patients with heart failure: a systematic review and meta-analysis","volume":"100","author":"Jin","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0037","doi-asserted-by":"crossref","first-page":"646","DOI":"10.21037\/jtd-22-78","article-title":"Systematic review and meta-analysis of the correlation between plasma homocysteine levels and coronary heart disease","volume":"14","author":"Wang","year":"2022","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0038","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nature09266","article-title":"From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus","volume":"466","author":"Musunuru","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.966890","article-title":"The association of plasma sortilin with essential hypertension and subclinical carotid atherosclerosis: a cross-sectional study","volume":"9","author":"Chu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.652584","article-title":"Sortilin as a biomarker for cardiovascular disease revisited","volume":"8","author":"M\u00f8ller","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0041","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1161\/ATVBAHA.116.308932","article-title":"Serum sortilin associates with aortic calcification and cardiovascular risk in men","volume":"37","author":"Goettsch","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0042","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s12291-018-0784-4","article-title":"New biomarkers as prognostic factors for cardiovascular complications in type 2 diabetic patients","volume":"35","author":"Ahmed","year":"2020","journal-title":"Indian J Clin Biochem"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155848","article-title":"Prognostic role of inflammatory cytokines and novel adipokines in acute myocardial infarction: an updated and comprehensive review","volume":"153","author":"Mitsis","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0044","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/0003319718771125","article-title":"Increased peripheral blood visfatin concentrations may be a risk marker of coronary artery disease: a meta-analysis of observational studies","volume":"69","author":"Yu","year":"2018","journal-title":"Angiology"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0045","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/4207499","article-title":"Visfatin related to the severity of non-ST-segment elevation acute coronary syndrome: a retrospective study of 164 patients at a tertiary chest pain center","volume":"2024","author":"Zheng","year":"2024","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0046","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12872-020-01549-3","article-title":"Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction","volume":"20","author":"Zheng","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0047","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0048","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O'Donoghue","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0049","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeae031","article-title":"Association between lipoprotein(a) and premature atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"4","author":"Tian","year":"2024","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0050","article-title":"Prognostic value of elevated lipoprotein (a) in patients with acute coronary syndromes: a systematic review and meta-analysis","volume":"11","author":"Wang","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0051","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0052","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0053","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0054","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0055","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0056","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0057","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102979","article-title":"Empagliflozin prevents oxidative stress in human coronary artery endothelial cells via the NHE\/PKC\/NOX axis","volume":"69","author":"Li","year":"2024","journal-title":"Redox Biol"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0059","doi-asserted-by":"crossref","first-page":"9935","DOI":"10.1007\/s00210-024-03225-1","article-title":"Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after coronary artery bypass grafting: a double-blind, randomized, placebo-controlled trial","volume":"397","author":"Zarei","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0060","doi-asserted-by":"crossref","first-page":"8986","DOI":"10.1038\/s41598-025-93483-7","article-title":"Empagliflozin demonstrates neuroprotective and cardioprotective effects by reducing ischemia\/reperfusion damage in rat models of ischemic stroke and myocardial infarction","volume":"15","author":"Dai","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2025.04.019_bib0061","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12933-021-01392-6","article-title":"Empagliflozin protects the heart against ischemia\/reperfusion-induced sudden cardiac death","volume":"20","author":"Hu","year":"2021","journal-title":"Cardiovasc Diabetol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825001626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825001626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:02:52Z","timestamp":1762246972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825001626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0149291825001626"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.04.019","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic and Prognostic Roles of Inflammatory Biomarkers in Patients With Coronary Heart Disease and Heart Failure Treated With Empagliflozin","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}